Previous 10 | Next 10 |
The FDA has rejected Helius Medical Technologies' (NASDAQ: HSDT ) application for De Novo status and 510(k) clearance of its Portable Neuromodulation Stimulator (PoNS). The agency cited the lack of sufficient information to determine the relative contributions of the PoNS device and physic...
NEWTOWN, Pa., April 02, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that first quarter of fiscal year 2019 financial results ...
PHOENIX, AZ / ACCESSWIRE / March 20, 2019 / Uptick Newswire Stock Day Podcast welcomed Helius Medical Technologies, Inc. (NASDAQ: HSDT) ("the Company"), a neurotech company focused on neurological wellness. President and CEO, Phil Deschamps, joined Stock Day host Everett Jolly. Jolly began ...
Helius Medical Technologies, Inc. (HSDT) Q4 2018 Earnings Conference Call March 14, 2019 04:30 PM ET Company Participants Phil Deschamps - CEO Joyce LaViscount - CFO and COO Conference Call Participants Steven Lichtman - Oppenheimer Sean Lavin - the BTIG Presentation ...
Helius Medical Technologies (NASDAQ: HSDT ): Q4 GAAP EPS of -$0.22 misses by $0.01 . More news on: Helius Medical Technologies, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the fourth quarter and full year ended December 31, 2018. Full Year 2018 Financi...
Noteworthy events during the week of March 10 - 16 for healthcare investors. More news on: Regeneron Pharmaceuticals, Inc., Sanofi, Roche Holding Ltd ADR, Healthcare stocks news, , Read more ...
NEWTOWN, Pa., March 06, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in Oppenheimer’s ...
T2 Biosystems (TTOO) T2 Magnetic Resonance ("MR") technology, powered through their T2Dx Instrument, is a diagnostic system that can do a variety of blood tests from inserted panels. They just had a big launch in mid-2018 for the T2Bacteria which got FDA approved in May 2018 that was suppose...
NEWTOWN, Pa., March 05, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has begun treating patients in Canada with the Com...
News, Short Squeeze, Breakout and More Instantly...
Helius Medical Technologies Inc. Company Name:
HSDT Stock Symbol:
NASDAQ Market:
NEWTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the C...